Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeDanish Financial Supervisory AuthorityOther stakeholders Date        6 July 2026 Share buyback programme – week 27 The share buyback programme runs in the period 6 May 2026 up to and including 7 August 2026, see company announcement of 6 May 2026. During the period the bank will thus buy back its own shares for a total of up to DKK 400 million under the programme, but to a maximum of 500,000 shares. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme:Date Number of shares Average purchase price (DKK) Total purchased under the programme (DKK)Total...

On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital. Gabriel Holding A/S held 55,109 treasury shares at the start of the share buyback programme. The buy-back is executed in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulation. The buy-back is carried out on Nasdaq Copenhagen at market price and in accordance with the authorization granted by the general meeting, Nasdaq Copenhagen’s rules for issuers, as well as Gabriel Holding A/S’ internal rules on insider matters...

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 1,350,096 907.69 1,225,462,95429 June 2026 12,317 943.23 11,617,77130 June 2026 12,384 945.23 11,705,7201 July 2026 12,213 950.11 11,603,6462...

HMS Networks AB (publ) will release its second quarter report of 2026 on Tuesday July 14th, 2026, at 07.30 CEST. On the same day, at 09.00 CEST, President and CEO Staffan Dahlström and CFO Joakim Nideborn present the report in a conference call for press and analysts. The presentation is in English and can be followed live via telephone or web. Slides used in the presentation will be made available on HMS’ website prior to the telephone conference. If you wish to participate via webcast, please use the link below. Link to webcast If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. Link to teleconference The presentation and recording of the telephone...

BEIJING, July 05, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China. Developed from InnoCare’s in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house invented payload via a protease-cleavable linker. This design enables significantly enhanced tumor-killing effects with improved stability and safety. CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive...

PERTH, Australia, July 05, 2026 (GLOBE NEWSWIRE) — Alkane Resources Limited (ASX: ALK; TSX: ALK; OTCQX: ALKRY) (‘Alkane’ or ‘the Company’) is pleased to announce the latest exploration results for extension and infill drilling of the True Blue deposit, located 2 km west of the active underground workings at its Costerfield Operation in central Victoria, Australia. Program SummaryAn additional 33 holes targeting the Freeman veining within the True Blue deposit have been drilled since Alkane’s previous update (ASX announcement 15 October 2025 titled ‘Costerfield Resource and Reserve Statement). The new drilling predominantly targeted infill of the upper portion of the deposit and has significantly increased confidence in understanding the vein geometry and grade-controlling structures. The higher resolution granted by the infill...